Cancer Management and Research
Volume 13, 2021 - Issue
Original Research
Cost-Effectiveness Analysis of Camrelizumab Immunotherapy versus Docetaxel or Irinotecan Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Ying-Tao Lin1 Administration Office of Drug Clinical Trial, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, People’s Republic of China
https://orcid.org/0000-0001-9168-0491
https://orcid.org/0000-0001-9168-0491, , Tian-Xiu Liu3 Department of Thoracic Radiotherapy, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, 350014, People’s Republic of Chinahttps://orcid.org/0000-0002-1575-5743
https://orcid.org/0000-0002-1575-5743, & 